This question is a slight variation of a question presented earlier. The FDA is properly anal about allowing drugs on the market ONLY based on solid evidence of safety & effectiveness of that drug.
I'd think getting RSVm accepted because of its pneumonia results would be unlikely...
But, WTF is up with a 40% breakout???
I've seen break-outs that are 4, 5, 6% and maybe 10%... but 40% is most unusual, even with Wainwright's target price.
Perhaps something is up, well beyond the Wainwright announcement????
I'm just wondering if that is true and what would be that truth...